Susquehanna Fundamental Investments LLC Acquires New Position in Cryoport, Inc. (NASDAQ:CYRX)

Susquehanna Fundamental Investments LLC bought a new position in shares of Cryoport, Inc. (NASDAQ:CYRX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 98,284 shares of the company’s stock, valued at approximately $765,000. Susquehanna Fundamental Investments LLC owned approximately 0.20% of Cryoport as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Avanza Fonder AB acquired a new stake in shares of Cryoport in the fourth quarter valued at $64,000. Nebula Research & Development LLC raised its position in Cryoport by 21.6% in the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock valued at $97,000 after purchasing an additional 2,207 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Cryoport by 135.5% in the 4th quarter. Russell Investments Group Ltd. now owns 12,875 shares of the company’s stock valued at $100,000 after buying an additional 7,407 shares during the period. Olympiad Research LP acquired a new position in shares of Cryoport during the fourth quarter worth about $103,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Cryoport during the fourth quarter worth approximately $111,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

Insider Buying and Selling at Cryoport

In related news, CEO Jerrell Shelton sold 4,620 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares in the company, valued at $4,814,359.71. The trade was a 0.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last three months, insiders have sold 19,830 shares of company stock worth $118,353. 10.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on CYRX shares. Guggenheim reiterated a “buy” rating and set a $10.00 price target on shares of Cryoport in a report on Wednesday, April 16th. Roth Mkm reissued a “buy” rating and issued a $15.00 target price on shares of Cryoport in a report on Tuesday, April 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Cryoport in a report on Wednesday, April 16th. Finally, UBS Group increased their price objective on Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.67.

Cryoport Stock Up 7.3 %

Cryoport stock opened at $5.86 on Friday. The company has a market capitalization of $293.80 million, a P/E ratio of -1.73 and a beta of 1.92. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $17.41. The stock has a 50-day simple moving average of $5.80 and a 200-day simple moving average of $6.90.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The firm had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same period in the previous year, the company posted ($0.29) earnings per share. Equities research analysts expect that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.